What happened
ST Bailing announced it received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its inhaled product BD77.
The notice, numbered 2026LP02645, permits the company to initiate clinical trials for the treatment of chronic obstructive pulmonary disease.
Why it matters
This approval marks a regulatory step forward for ST Bailing's inhaled candidate, potentially expanding its pipeline in respiratory disease.
If the trials succeed, inhaled BD77 could offer a new treatment option for COPD, though efficacy and safety will determine its eventual viability.
Key facts
The approval was issued by the National Medical Products Administration.
The clinical trial is authorized for chronic obstructive pulmonary disease.
The approval notice number is 2026LP02645.
What to watch next
Further disclosures from ST Bailing regarding the trial design, patient recruitment, and expected timeline.
Early safety and efficacy data from the trial, which will be critical in assessing the drug's potential.